Equities research analysts forecast that Omeros Co. (NASDAQ:OMER) will post ($0.54) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Omeros’ earnings. The lowest EPS estimate is ($0.70) and the highest is ($0.38). Omeros posted earnings of ($0.16) per share in the same quarter last year, which indicates a negative year over year growth rate of 237.5%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 13th.
On average, analysts expect that Omeros will report full-year earnings of ($1.66) per share for the current financial year, with EPS estimates ranging from ($1.80) to ($1.52). For the next year, analysts anticipate that the company will report earnings of ($2.09) per share, with EPS estimates ranging from ($4.27) to $0.10. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Omeros.
Omeros (NASDAQ:OMER) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.19). The firm had revenue of $23.54 million for the quarter, compared to analysts’ expectations of $30.92 million.
In other news, Director Thomas J. Cable sold 5,000 shares of Omeros stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $14.40, for a total value of $72,000.00. Following the completion of the transaction, the director now owns 40,067 shares in the company, valued at approximately $576,964.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.30% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. American International Group Inc. raised its position in shares of Omeros by 2.5% during the 1st quarter. American International Group Inc. now owns 30,285 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 727 shares in the last quarter. Rocky Mountain Advisers LLC grew its stake in shares of Omeros by 5.7% in the 1st quarter. Rocky Mountain Advisers LLC now owns 16,160 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 875 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Omeros by 52.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,242 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 1,463 shares during the last quarter. Swiss National Bank grew its stake in shares of Omeros by 2.2% in the 4th quarter. Swiss National Bank now owns 89,600 shares of the biopharmaceutical company’s stock valued at $1,262,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in shares of Omeros by 24.7% in the 4th quarter. Victory Capital Management Inc. now owns 10,245 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 2,030 shares during the last quarter. Institutional investors and hedge funds own 57.44% of the company’s stock.
Omeros stock traded down $0.27 during trading hours on Wednesday, reaching $14.88. The stock had a trading volume of 383,300 shares, compared to its average volume of 690,267. The company has a market cap of $802.01 million, a price-to-earnings ratio of -8.66 and a beta of 1.89. The business’s 50 day moving average price is $15.07 and its 200-day moving average price is $13.92. Omeros has a 52 week low of $8.50 and a 52 week high of $20.92.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: What is the CAC 40 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.